Royalty Pharma acquires royalty interest in olpasiran for $250m
Pharmaceutical Technology
NOVEMBER 10, 2022
Royalty Pharma has purchased a royalty interest in Amgen ’s small interfering ribonucleic acid (siRNA) therapy, olpasiran, from Arrowhead Pharmaceuticals for an upfront payment of $250m in cash. Additionally, Royalty Pharma is entitled to receive further payments of up to $160m subject to meeting some clinical, regulatory and sales milestones. According to the deal, Royalty Pharma will acquire Arrowhead’s complete royalty interest in olpasiran, which amounts to a royalty of up to the low double
Let's personalize your content